Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Novopharm ranitidine

This article was originally published in The Tan Sheet

Executive Summary

Novopharm ranitidine: Company will market its Form 1 generic version of the prescription H2 antagonist on July 10, 16 days prior to expiration of Glaxo Wellcome's patent protection for Zantac (Form 2 ranitidine), pursuant to a licensing agreement announced April 24. The Form 1 patent expires July 25. Novopharm will pay Glaxo licensing fees in return for the 16-day generic exclusivity. Glaxo agreed not to appeal its Form 1 patent cases against Novopharm to the Supreme Court after a federal appeals court affirmed April 6 a lower court decision that Novopharm should be allowed to market its Form 1 generic after July 25 ("The Tan Sheet" Jan. 13, p. 19)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel